Merck Bolsters Oncology Portfolio with Another Acquisition
Merck has been active in dealmaking recently completing its acquisitions of ArQule and Themis.
Pharmaceuticals
Bayer Spends Up to $4 Billion for AskBio’s Gene Therapies
Drugmakers including Novartis, Roche Holding and Bristol-Myers Squibb have snapped up makers of gene therapies because they offer potential to cure a wide range of often-rare diseases by replacing or repairing errors in the body’s instruction manual.
M&A Wrap: Q3 Rebound, Bristol-Myers, Monroe Capital, Avante Capital, MyoKardia, Alibaba, Greenbriar, Uber, Thoma Bravo
Bristol Myers buys heart drug developer. Lending executives including Monroe's Theodore Koenig and Avante's Jeri Harman talk about M&A bouncing back. Greenbriar invests in Uber's logistics arm.
Bristol-Myers Buys Heart Drug Maker MyoKardia for $13 Billion
Expanding Bristol-Myers’s lineup of heart drugs would help the maker of Opdivo for cancer diversify beyond oncology, an area where much of the industry has focused in recent years.
UnitedHealth reportedly in talks to buy pharmacy startup DivvyDose
Traditional health insurers are increasingly diversifying into other healthcare service businesses, including care delivery, pharmacy benefits, and technology.
Illumina buys healthcare startup Grail
Grail, originally founded by Illumina and later spun out as a standalone company, is developing a blood test that aims to detect cancers early. The company has high profile tech and healthcare backers, including Bill Gates, Jeff Bezos, Merck and Johnson & Johnson.
Join our Membership
Join the Merger & Acquisitions community to access premium content and exclusive member-only benefits.
Become a member
M&A wrap: Gilead, Immunomedics, Trodelvy, Nvidia, Softbank, Verizon, TH Lee, FP, HGGC
Merger Monday: Gilead buys Immunomedics to boost cancer treatment portfolio. Nvidia purchases Softbank's chip division. Verizon buys Tracfone. PE news from TH Lee and FP.
Gilead ramps up cancer focus with $21 billion Immunomedics deal
Acquiring Immunomedics will give Gilead an immediate presence in the enormous market for drugs that treat solid tumors such as breast cancer, complementing its medicines like Yescarta that are focused on blood tumors.
M&A wrap: AstraZeneca, Sanofi, J&J, GSK, Blackstone, Carlyle, TA, Centerbridge, AEI, Genstar, Alera, Race for Vaccines
Pharmaceutical giants including AstraZeneca, GlaxoSmithKline and J&J race to develop a coronavirus vaccine. Blackstone Group and Global Infrastructure Partners reportedly offer to buy railroad operator Kansas City Southern. Roark buys ServiceMaster Brands.